Labetuzumab govitecan
Monoclonal antibody
From Wikipedia, the free encyclopedia
Labetuzumab govitecan (IMMU-130) is an antibody–drug conjugate (ADC) that was investigated for the treatment of colorectal cancer.[1] Labetuzumab has also been evaluated in patients with metastatic medullary thyroid carcinoma (MTC).[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | carcinoembryonic antigen |
| Clinical data | |
| Other names | IMMU 130 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
The parent antibody, labetuzumab, is a humanized IgG1 monoclonal antibody[3] that selectively binds to carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).[4] In the ADC, the antibody is covalently linked to SN-38, the active metabolite of the topoisomerase I inhibitor irinotecan.
The drug was developed by Immunomedics, Inc.[5]
